Skip to main content
[Preprint]. 2022 Sep 26:2022.09.26.509529. [Version 1] doi: 10.1101/2022.09.26.509529

Figure 2. dNSP16 is attenuated in human respiratory cells and is more sensitive to type I interferon (IFN-I) pre-treatment.

Figure 2.

(a) Replication of WT (black) and dNSP16 (blue) in Calu-3 2B4 cells, MOI = 0.01. ****p<0.001: results of two-way ANOVA with Tukey’s multiple comparison test (α = 0.05). (b) Replication of WT (black) and dNSP16 (blue) in Vero E6 cells without IFN-I (solid lines, data as in Fig. 1c), or with 100 U IFN pre-treatment a day prior to infection (dashed lines), multiplicity of infection = 0.01. (c) Comparison of the viral titers at 48 hours post-infection from panel (b), with additional treatment levels of IFN-I indicated. ****p<0.001: results of two-way ANOVA with Tukey’s multiple comparison test (α = 0.05). Means are plotted with error bars denoting standard deviation. For all panels, n = 3 for all data points. Dotted lines represent limits of detection. PFU = plaque-forming units.